Loading...
•
Dec 31, 2020
Cronos Q4 2020 Earnings Report
Cronos Group's Q4 2020 results reflected hard work and perseverance, with revenue growth driven by the adult-use market in Canada, sales in the Israeli medical market, and growth in the U.S. segment, partially offset by strategic price reductions in Canada.
Key Takeaways
Cronos Group's Q4 2020 net revenue increased by $9.7 million compared to Q4 2019, primarily driven by growth in the adult-use market in Canada, sales in the Israeli medical market, and growth in the U.S. segment. The company's gross loss decreased by $5.2 million year-over-year, while the adjusted EBITDA loss increased by $1.5 million.
Net revenue of $17.0 million in Q4 2020 increased by $9.7 million from Q4 2019.
Gross loss of $14.9 million in Q4 2020 decreased by $5.2 million from Q4 2019.
The Company incurred an inventory write-down in Q4 2020 of $15.0 million on dried cannabis and cannabis extracts.
Adjusted EBITDA loss of $53.1 million in Q4 2020 increased by $1.5 million from Q4 2019.
Cronos
Cronos
Cronos Revenue by Segment
Cronos Revenue by Geographic Location
Revenue by Segment
United States Revenue
CapyFin.comRest of World Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Cronos Group did not provide specific financial guidance for future periods in this earnings report.
Revenue & Expenses
Visualization of income flow from segment revenue to net income